ROIVRoivant Sciences Ltd.

$36.77

$11.1752 weeks$37.41

Price

$36.77+218%1Y

1M+4.8%1Y+218%

Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.

Smart Score

Above average

7/10

Value76

Quality39

Momentum88

Growth11

Strongest Momentum, weakest Growth · ranked vs Healthcare peers. The five questions below judge the company on its own terms.

What they do

Roivant is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter.

In the company’s own words · 10-K filed May 20, 2026 · SEC EDGAR

P/E (TTM)-

Market Cap$22.61B

1Y Return+218%

5Y Return+272%

Roivant Sciences Ltd. (ROIV) reported revenue of $2.5M in Q4 2025 (quarter ended March 31, 2026), down 67% from the same quarter a year earlier. That came with net income of $303M (12024% of revenue). For the full year FY2025, revenue was $8.3M (−72% year on year) and net income −$300M.

Raw charts

9 series · TTM

As reported to the SEC, without any scoring.

Biotechnology

Ranks #77 of 145 by Smart Score